ManagedCareCGM.com Presents: Innovations in rtCGM to Improve Clinical Outcomes in Diabetes.

Learn About:

• Clinical evidence and professional society guidelines for CGM systems
• The impact of rtCGM on clinical measures of diabetes care
• The implementation of medical and pharmacy benefit design strategies

Expert Faculty Presenters:

Matthew D. Harman, PharmD, MPH VP, Clinical Solutions Employers Health Click here for biography Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP Endocrine Clinical Pharmacy Specialist Co-Director, Endocrine Disorders in Pregnancy Cleveland Clinic Endocrinology & Metabolism Institute Click here for biography Gary A. Puckrein, PhD President and Chief Executive Officer National Minority Quality Forum Click here for biography Drake Reiter, PharmD Advisor, Pharmacy Product & Trend Priority Health Click here for biography

Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.

Statement of Need/Program Overview
Continuous glucose monitoring (CGM) offers immediate assessment of glucose levels and trends. CGMs can provide alerts when glucose levels exceed low or high thresholds or are changing rapidly, allowing patients to adjust insulin dosing or consume carbohydrates to minimize the risk of hypoglycemia. CGM technology also offers key insights for clinicians—including pharmacy professionals—and offers an opportunity for enhanced patient engagement and lifestyle modification. Professional organizations continue to expand recommendations supporting CGM use in patient care protocols in a broader population of patients with type 1, type 2, and gestational diabetes. Current guidelines, emerging clinical evidence, and a presentation of case studies will illustrate the opportunity for real-time CGM (rtCGM) to measurably improve care quality and outcomes for patients with diabetes. Pertinent to managed care decision makers, the discussion will include pharmacy benefit design to improve patient access to rtCGM.

Educational Objectives
After completing this activity, the participant should be better able to:

• Assess clinical evidence and professional society guidelines for CGM systems in patients with type 1 or type 2 diabetes
• Characterize the impact of rtCGM on clinical measures of diabetes care
• Implement medical and pharmacy benefit design strategies to support appropriate access to rtCGM and develop evidence-based clinical criteria

Accreditation Information

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Impact Education, LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Medical Education Resources designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Continuing Pharmacy Education
Medical Education Resources designates this continuing education activity for 1.5 contact hour (0.15 CEU) of the Accreditation Council for Pharmacy Education.

UAN: JA0003680-9999-23-137-L01-P
Type of Activity: Knowledge

Disclosure of Conflicts of Interest
Medical Education Resources insures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies relevant financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity. Registration for AMCP 2023 is NOT required to attend.